Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 220

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives

Open access
Ontaneda, Daniel, Fox, Robert J, Chataway, Jeremy · 2015 · The Lancet Neurology

Abstract

Progressive multiple sclerosis is characterized by the gradual accrual of disability independent of relapses and can occur with disease onset (primary progressive) or preceded by a relapsing disease course (secondary progressive). An effective disease modifying treatment for progressive multiple sclerosis has not been identified, and the results of clinical trials to date have been generally disappointing. Ongoing advances in our understanding of pathogenesis, identification of novel targets for neuro-protection, and improved outcome measures have the potential to lead to effective treatments for progressive multiple sclerosis. In this review lessons learned from previous clinical trials and perspectives from current trials in progressive multiple sclerosis are summarized. Promising clinical, imaging, and biological markers will also be reviewed, along with novel clinical trial designs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1474-4422(14)70264-9

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Research works printed but not linked: 152

  1. Mahad, 2015, Pathological mechanisms in progressive multiple sclerosis, Lancet Neurol, 14, 183, 10.1016/S1474-4422(14)70256-X · DOI · Paper page
  2. Miller, 2012, Treatment of relapsing-remitting multiple sclerosis: current approaches and unmet needs, Curr Opin Neurol, 25, S4, 10.1097/01.wco.0000413319.87092.19 · DOI
  3. Wiendl, 2009, Multiple sclerosis therapeutics: unexpected outcomes clouding undisputed successes, Neurology, 72, 1008, 10.1212/01.wnl.0000344417.42972.54 · DOI
  4. 1988, Double-masked trial of azathioprine in multiple sclerosis, Lancet, 332, 179
  5. 1990, Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial, Ann Neurol, 27, 591, 10.1002/ana.410270603 · DOI · Paper page
  6. 1991, The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis, Lancet, 337, 441, 10.1016/0140-6736(91)93389-Q · DOI · Paper page
  7. Noseworthy, 1998, The Mayo Clinic-Canadian Cooperative trial of sulfasalazine in active multiple sclerosis, Neurology, 51, 1342, 10.1212/WNL.51.5.1342 · DOI
  8. Kappos, 1998, Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis, Lancet, 352, 1491, 10.1016/S0140-6736(98)10039-9 · DOI · Paper page
  9. Noseworthy, 2000, Linomide in relapsing and secondary progressive MS: part I: trial design and clinical results. North American Linomide Investigators, Neurology, 54, 1726, 10.1212/WNL.54.9.1726 · DOI · Paper page
  10. Rice, 2000, Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI study group, Neurology, 54, 1145, 10.1212/WNL.54.5.1145 · DOI · Paper page
  11. 2001, Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results, Neurology, 56, 1496, 10.1212/WNL.56.11.1496 · DOI · Paper page
  12. Cohen, 2002, Benefit of interferon beta-1a on MSFC progression in secondary progressive MS, Neurology, 59, 679, 10.1212/WNL.59.5.679 · DOI · Paper page
  13. Hartung, 2002, Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial, Lancet, 360, 2018, 10.1016/S0140-6736(02)12023-X · DOI · Paper page
  14. Andersen, 2004, Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis, J Neurol Neurosurg Psychiatry, 75, 706, 10.1136/jnnp.2003.010090 · DOI
  15. Hommes, 2004, Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial, Lancet, 364, 1149, 10.1016/S0140-6736(04)17101-8 · DOI · Paper page
  16. Pohlau, 2007, Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study, Mult Scler, 13, 1107, 10.1177/1352458507078400 · DOI
  17. Wolinsky, 2007, Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial, Ann Neurol, 61, 14, 10.1002/ana.21079 · DOI · Paper page
  18. Hawker, 2009, Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial, Ann Neurol, 66, 460, 10.1002/ana.21867 · DOI · Paper page
  19. Freedman, 2011, A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS, Neurology, 77, 1551, 10.1212/WNL.0b013e318233b240 · DOI
  20. Zajicek, 2013, Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial, Lancet Neurol, 12, 857, 10.1016/S1474-4422(13)70159-5 · DOI
  21. Brochet, 2013, Double-blind, randomized, controlled study of cyclophosphamide versus methylprednisolone in secondary progressive multiple sclerosis: PROMESS study, Multiple sclerosis (Houndmills, Basingstoke, England), 19, 51
  22. Khatri, 1985, Chronic progressive multiple sclerosis: Double-blind controlled study of plasmapheresis in patients taking immunosuppressive drugs, Neurology, 35, 312, 10.1212/WNL.35.3.312 · doi:10.1212/wnl.35.3.312
  23. Gordon, 1985, A double-blind controlled pilot study of plasma exchange versus sham apheresis in chronic progressive multiple sclerosis, Can J Neurol Sci, 12, 39, 10.1017/S0317167100046564 · doi:10.1017/s0317167100046564
  24. Cook, 1986, Effect of total lymphoid irradiation in chronic progressive multiple sclerosis, Lancet, 1, 1405, 10.1016/S0140-6736(86)91554-0 · doi:10.1016/s0140-6736(86)91554-0
  25. Kastrukoff, 1990, Systemic lymphoblastoid interferon therapy in chronic progressive multiple sclerosis. I. Clinical and MRI evaluation, Neurology, 40, 479, 10.1212/WNL.40.3_Part_1.479 · DOI
  26. Bornstein, 1991, A placebo-controlled, double-blind, randomized, two-center, pilot trial of cop 1 in chronic progressive multiple sclerosis, Neurology, 41, 533, 10.1212/WNL.41.4.533 · DOI · Paper page
  27. Sipe, 1994, Cladribine in treatment of chronic progressive multiple sclerosis, Lancet, 344, 9, 10.1016/S0140-6736(94)91046-4 · DOI · Paper page
  28. Wiles, 1994, Total lymphoid irradiation in multiple sclerosis, J Neurol Neurosurg Psychiatry, 57, 154, 10.1136/jnnp.57.2.154 · doi:10.1136/jnnp.57.2.154
  29. Milligan, 1994, A placebo-controlled trial of isoprinosine in patients with multiple sclerosis, J Neurol Neurosurg Psychiatry, 57, 164, 10.1136/jnnp.57.2.164 · DOI
  30. Goodkin, 1995, Low-dose (7·5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis, Ann Neurol, 37, 30, 10.1002/ana.410370108 · DOI · Paper page
  31. Cazzato, 1995, Double-blind, placebo-controlled, randomized, crossover trial of high-dose methylprednisolone in patients with chronic progressive form of multiple sclerosis, Eur Neurol, 35, 193, 10.1159/000117127 · doi:10.1159/000117127
  32. Karussis, 1996, Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: a double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation, Neurology, 47, 341, 10.1212/WNL.47.2.341 · doi:10.1212/wnl.47.2.341
  33. van Oosten, 1997, Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial, Neurology, 49, 351, 10.1212/WNL.49.2.351 · DOI · Paper page
  34. Cook, 1997, Modified total lymphoid irradiation and low dose corticosteroids in progressive multiple sclerosis, J Neurol Sci, 152, 172, 10.1016/S0022-510X(97)00189-5 · doi:10.1016/s0022-510x(97)00189-5
  35. Bosco, 1997, A randomized, placebo-controlled, double-blind study on the efficacy of idebenone administered to patients suffering from chronic-progressive form of multiple sclerosis and are submitted to recurrent treatment with high dose of methylprednisolone, Nuova Rivista di Neurologia, 7, 90
  36. Goodkin, 1998, A phase II study of i.v. methylprednisolone in secondary-progressive multiple sclerosis, Neurology, 51, 239, 10.1212/WNL.51.1.239 · doi:10.1212/wnl.51.1.239
  37. Paolillo, 1999, Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody campath 1H, Neurology, 53, 751, 10.1212/WNL.53.4.751 · DOI · Paper page
  38. Coles, 2006, The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy, J Neurol, 253, 98, 10.1007/s00415-005-0934-5 · DOI · Paper page
  39. Skurkovich, 2001, Randomized study of antibodies to IFN-gamma and TNF-alpha in secondary progressive multiple sclerosis, Mult Scler, 7, 277
  40. Leary, 2003, Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial, Neurology, 60, 44, 10.1212/WNL.60.1.44 · DOI · Paper page
  41. Walker, 2005, A double-blind, randomized, controlled study of oral pirfenidone for treatment of secondary progressive multiple sclerosis, Mult Scler, 11, 149, 10.1191/1352458505ms1134oa · doi:10.1191/1352458505ms1134oa
  42. Warren, 2006, Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA class II-defined cohort of patients with progressive multiple sclerosis: results of a 24-month double-blind placebo-controlled clinical trial and 5 years of follow-up treatment, Eur J Neurol, 13, 887, 10.1111/j.1468-1331.2006.01533.x · DOI
  43. Montanari, 2009, ASPIRE (azathioprine secondary progressive interferon treated patients randomised evaluation) study: 2-year double-blind and 1-year open, randomised, multicentre, pilot study. Multiple sclerosis functional composite (MSFC) and magnetic resonance data, Mult Scler (Houndmills, Basingstoke, England), 250, 822
  44. Montalban, 2009, A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis, Mult Scler, 15, 1195, 10.1177/1352458509106937 · DOI
  45. Kapoor, 2010, Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial, Lancet Neurol, 9, 681, 10.1016/S1474-4422(10)70131-9 · DOI · Paper page
  46. Karpha, 2010, PAW25 a single-centre, pilot, randomised controlled trial of recombinant human erythropoietin in primary progressive multiple sclerosis, J Neurol Neurosurg Psychiatry, 81, e30, 10.1136/jnnp.2010.226340.53 · doi:10.1136/jnnp.2010.226340.53
  47. Barkhof, 2010, Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant?, Neurology, 74, 1033, 10.1212/WNL.0b013e3181d7d651 · DOI
  48. Vollmer, 2011, A phase 2, 24-week, randomized, placebo-controlled, double-blind study examining the efficacy and safety of an anti-interleukin-12 and -23 monoclonal antibody in patients with relapsing-remitting or secondary progressive multiple sclerosis, Mult Scler, 17, 181, 10.1177/1352458510384496 · DOI
  49. Connick, 2012, Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study, Lancet Neurol, 11, 150, 10.1016/S1474-4422(11)70305-2 · DOI · Paper page
  50. Vermersch, 2012, Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study, BMC Neurol, 12, 36, 10.1186/1471-2377-12-36 · DOI
  51. Arun, 2013, Targeting ASIC1 in primary progressive multiple sclerosis: evidence of neuroprotection with amiloride, Brain, 136, 106, 10.1093/brain/aws325 · DOI
  52. Mostert, 2013, The effect of fluoxetine on progression in progressive multiple sclerosis: a double-blind, randomized, placebo-controlled trial, ISRN Neurol, 2013, 370943, 10.1155/2013/370943 · DOI
  53. Chataway, 2014, Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial, Lancet, 383, 2213, 10.1016/S0140-6736(13)62242-4 · DOI · Paper page
  54. Casetta, 2007, Azathioprine for multiple sclerosis, Cochrane Database Syst Rev, 4, 10.1002/14651858.CD003982.pub2 · DOI
  55. La Mantia, 2007, Cyclophosphamide for multiple sclerosis, Cochrane Database Syst Rev, 1, 10.1002/14651858.CD002819.pub2 · doi:10.1002/14651858.cd002819.pub2
  56. Reston, 2011, Autologous hematopoietic cell transplantation for multiple sclerosis: a systematic review, Mult Scler, 17, 204, 10.1177/1352458510383609 · DOI
  57. Spelman, 2013, Defining secondary progressive multiple sclerosis: is it possible to diagnose early?, Mult Scler, 19, 38
  58. Miller, 2008, Differential diagnosis of suspected multiple sclerosis: a consensus approach, Mult Scler, 14, 1157, 10.1177/1352458508096878 · DOI · Paper page
  59. Marrie, 2008, Comorbidity, socioeconomic status and multiple sclerosis, Mult Scler, 14, 1091, 10.1177/1352458508092263 · DOI · Paper page
  60. Manouchehrinia, 2013, Tobacco smoking and disability progression in multiple sclerosis: United kingdom cohort study, Brain, 136, 2298, 10.1093/brain/awt139 · DOI · Paper page
  61. Ascherio, 2014, Vitamin D as an early predictor of multiple sclerosis activity and progression, JAMA Neurol, 71, 306, 10.1001/jamaneurol.2013.5993 · DOI · Paper page
  62. Kappos, 2001, Final analysis of the European multicenter trial on IFNbeta-1b in secondary-progressive MS, Neurology, 57, 1969, 10.1212/WNL.57.11.1969 · DOI
  63. Mantia, 2013, Interferon β for secondary progressive multiple sclerosis: a systematic review, J Neurol Neurosurg Psychiatry, 84, 420, 10.1136/jnnp-2012-303291 · DOI
  64. van der Graaf, 2012, Adaptive trials in clinical research: scientific and ethical issues to consider, JAMA, 307, 2379, 10.1001/jama.2012.6380 · DOI
  65. Wason, 2014, Adaptive designs for clinical trials assessing biomarker-guided treatment strategies, Br J Cancer, 110, 1950, 10.1038/bjc.2014.156 · DOI
  66. Thall, 2000, Evaluating multiple treatment courses in clinical trials, Stat Med, 19, 1011, 10.1002/(SICI)1097-0258(20000430)19:8<1011::AID-SIM414>3.0.CO;2-M · doi:10.1002/(sici)1097-0258(20000430)19:8<1011::aid-sim414>3.0.co;2-m
  67. Muller, 2001, Adaptive group sequential designs for clinical trials: combining the advantages of adaptive and of classical group sequential approaches, Biometrics, 57, 886, 10.1111/j.0006-341X.2001.00886.x · DOI · Paper page
  68. Friede, 2011, Designing a seamless phase II/III clinical trial using early outcomes for treatment selection: an application in multiple sclerosis, Stat Med, 30, 1528, 10.1002/sim.4202 · DOI
  69. Chataway, 2011, A novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosis, Mult Scler, 17, 81, 10.1177/1352458510382129 · DOI
  70. Rudick, 2014, Multiple sclerosis outcome assessments consortium: genesis and initial project plan, Mult Scler, 20, 12, 10.1177/1352458513503392 · DOI
  71. Barkhof, 2011, MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials, Nat Rev Neurol, 8, 13, 10.1038/nrneurol.2011.190 · DOI
  72. Hobart, 2000, Kurtzke scales revisited: the application of psychometric methods to clinical intuition, Brain, 123, 1027, 10.1093/brain/123.5.1027 · DOI · Paper page
  73. Noseworthy, 1990, Interrater variability with the expanded disability status scale (EDSS) and functional systems (FS) in a multiple sclerosis clinical trial. The Canadian Cooperation MS Study Group, Neurology, 40, 971, 10.1212/WNL.40.6.971 · DOI · Paper page
  74. Whitaker, 1995, Outcomes assessment in multiple sclerosis clinical trials: a critical analysis, Mult Scler, 1, 37, 10.1177/135245859500100107 · DOI · Paper page
  75. Hobart, 2004, Outcome measures for multiple sclerosis clinical trials: relative measurement precision of the expanded disability status scale and multiple sclerosis functional composite, Mult Scler, 10, 41, 10.1191/1352458504ms983oa · DOI
  76. Verdier-Taillefer, 1991, Observer disagreement in rating neurologic impairment in multiple sclerosis: facts and consequences, Eur Neurol, 31, 117, 10.1159/000116658 · doi:10.1159/000116658
  77. Lamers, 2014, Assessing upper limb function in multiple sclerosis, Mult Scler, 20, 775, 10.1177/1352458514525677 · DOI
  78. Brissart, 2010, Integration of cognitive impairment in the expanded disability status scale of 215 patients with multiple sclerosis, Eur Neurol, 64, 345, 10.1159/000322140 · DOI
  79. Kragt, 2008, Responsiveness and predictive value of EDSS and MSFC in primary progressive MS, Neurology, 70, 1084, 10.1212/01.wnl.0000288179.86056.e1 · DOI
  80. Rudick, 1997, Recommendations from the national multiple sclerosis society clinical outcomes assessment task force, Ann Neurol, 42, 379, 10.1002/ana.410420318 · DOI · Paper page
  81. Cutter, 1999, Development of a multiple sclerosis functional composite as a clinical trial outcome measure, Brain, 122, 871, 10.1093/brain/122.5.871 · DOI · Paper page
  82. Rudick, 2002, The multiple sclerosis functional composite: a new clinical outcome measure for multiple sderosis trials, Mult Scler, 8, 359, 10.1191/1352458502ms845oa · DOI · Paper page
  83. Miller, 2000, Clinical significance of the multiple sclerosis functional composite: relationship to patient-reported quality of life, Arch Neurol, 57, 1319, 10.1001/archneur.57.9.1319 · DOI
  84. Rudick, 2009, Assessing disability progression with the multiple sclerosis functional composite, Mult Scler, 15, 984, 10.1177/1352458509106212 · DOI
  85. Costelloe, 2008, The longitudinal relationship between the patient-reported multiple sclerosis impact scale and the clinician-assessed multiple sclerosis functional composite, Mult Scler, 14, 255, 10.1177/1352458507081274 · doi:10.1177/1352458507081274
  86. Ozakbas, 2004, Correlations between multiple sclerosis functional composite, expanded disability status scale and health-related quality of life during and after treatment of relapses in patients with multiple sclerosis, J Neurol Sci, 218, 3, 10.1016/j.jns.2003.09.015 · DOI
  87. Cohen, 2002, Benefit of interferon beta-1a on MSFC progression in secondary progressive MS, Neurology, 59, 679, 10.1212/WNL.59.5.679 · DOI · Paper page
  88. Kalkers, 2001, Concurrent validity of the MS functional composite using MRI as a biological disease marker, Neurology, 56, 215, 10.1212/WNL.56.2.215 · DOI
  89. Fisher, 2000, Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients, Mult Scler, 6, 373, 10.1177/135245850000600602 · DOI · Paper page
  90. Cadavid, 2011, Clinical consequences of MRI activity in treated multiple sclerosis, Mult Scler, 17, 1113, 10.1177/1352458511405375 · DOI
  91. Kappos, 2010, A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis, N Engl J Med, 362, 387, 10.1056/NEJMoa0909494 · DOI · Paper page
  92. Fox, 2007, Optimal reference population for the multiple sclerosis functional composite, Mult Scler, 13, 909, 10.1177/1352458507076950 · DOI
  93. Kragt, 2006, Clinical impact of 20% worsening on timed 25-foot walk and 9-hole peg test in multiple sclerosis, Mult Scler, 12, 594, 10.1177/1352458506070768 · DOI · Paper page
  94. Rudick, 2009, Assessing disability progression with the multiple sclerosis functional composite, Mult Scler, 15, 984, 10.1177/1352458509106212 · DOI
  95. Balcer, 2003, Contrast letter acuity as a visual component for the multiple sclerosis functional composite, Neurology, 61, 1367, 10.1212/01.WNL.0000094315.19931.90 · DOI · Paper page
  96. Ontaneda, 2012, Revisiting the multiple sclerosis functional composite: proceedings from the national multiple sclerosis society (NMSS) task force on clinical disability measures, Mult Scler, 18, 1074, 10.1177/1352458512451512 · DOI
  97. Brochet, 2008, Should SDMT substitute for PASAT in MSFC? A 5-year longitudinal study, Mult Scler, 14, 1242, 10.1177/1352458508094398 · DOI
  98. Julian, 2011, Cognitive functioning in multiple sclerosis, Neurol Clin, 29, 507, 10.1016/j.ncl.2010.12.003 · DOI
  99. Bever, 1995, The brief repeatable battery of neuropsychological tests for multiple sclerosis: a preliminary serial study, Mult Scler, 1, 165, 10.1177/135245859500100306 · DOI
  100. Buschke, 1974, Evaluating storage, retention, and retrieval in disordered memory and learning, Neurology, 24, 1019, 10.1212/WNL.24.11.1019 · DOI · Paper page
  101. Barbizet, 1968, Clinical and psychometrical study of a patient with memory disturbances, Int J Neurol, 7, 44
  102. Benedict, 2008, Repeated assessment of neuropsychological deficits in multiple sclerosis using the symbol digit modalities test and the MS neuropsychological screening questionnaire, Mult Scler, 14, 940, 10.1177/1352458508090923 · DOI · Paper page
  103. Borkowski, 1967, Word fluency and brain damage, Neuropsychologia, 5, 135, 10.1016/0028-3932(67)90015-2 · DOI · Paper page
  104. Strober, 2009, Sensitivity of conventional memory tests in multiple sclerosis: comparing the rao brief repeatable neuropsychological battery and the minimal assessment of cognitive function in MS, Mult Scler, 15, 1077, 10.1177/1352458509106615 · DOI · Paper page
  105. Benedict, 2012, Reliability and equivalence of alternate forms for the symbol digit modalities test: implications for multiple sclerosis clinical trials, Mult Scler, 18, 1320, 10.1177/1352458511435717 · DOI
  106. Sonder, 2014, Comparing long-term results of PASAT and SDMT scores in relation to neuropsychological testing in multiple sclerosis, Mult Scler, 20, 481, 10.1177/1352458513501570 · DOI
  107. Benedict, 2012, Brief international cognitive assessment for MS (BICAMS): international standards for validation, BMC Neurol, 12, 55, 10.1186/1471-2377-12-55 · DOI · Paper page
  108. Johnson, 1998, Valuation of EuroQOL (EQ-5D) health states in an adult US sample, Pharmacoeconomics, 13, 421, 10.2165/00019053-199813040-00005 · DOI · Paper page
  109. Ware, 1992, The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection, Med Care, 30, 473, 10.1097/00005650-199206000-00002 · DOI · Paper page
  110. Fisk, 2005, A comparison of health utility measures for the evaluation of multiple sclerosis treatments, J Neurol Neurosurg Psychiatry, 76, 58, 10.1136/jnnp.2003.017897 · DOI · Paper page
  111. Hobart, 2001, The multiple sclerosis impact scale (MSIS-29): a new patient-based outcome measure, Brain, 124, 962, 10.1093/brain/124.5.962 · DOI · Paper page
  112. Hayton, 2012, Clinical and imaging correlates of the multiple sclerosis impact scale in secondary progressive multiple sclerosis, J Neurol, 259, 237, 10.1007/s00415-011-6151-5 · DOI
  113. Kuhlmann, 2002, Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time, Brain, 125, 2202, 10.1093/brain/awf235 · DOI · Paper page
  114. De Stefano, 2010, Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes, Neurology, 74, 1868, 10.1212/WNL.0b013e3181e24136 · DOI · Paper page
  115. Rudick, 2000, Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon beta-1a, Mult Scler, 6, 365, 10.1177/135245850000600601 · DOI
  116. Altmann, 2009, Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis, Neurology, 72, 595, 10.1212/01.wnl.0000335765.55346.fc · DOI
  117. Bermel, 2006, The measurement and clinical relevance of brain atrophy in multiple sclerosis, Lancet Neurol, 5, 158, 10.1016/S1474-4422(06)70349-0 · DOI · Paper page
  118. Tedeschi, 2005, Brain atrophy and lesion load in a large population of patients with multiple sclerosis, Neurology, 65, 280, 10.1212/01.wnl.0000168837.87351.1f · DOI
  119. Fisher, 2008, Gray matter atrophy in multiple sclerosis: a longitudinal study, Ann Neurol, 64, 255, 10.1002/ana.21436 · DOI · Paper page
  120. Fisniku, 2008, Gray matter atrophy is related to long-term disability in multiple sclerosis, Ann Neurol, 64, 247, 10.1002/ana.21423 · DOI · Paper page
  121. Amato, 2007, Association of neocortical volume changes with cognitive deterioration in relapsing-remitting multiple sclerosis, Arch Neurol, 64, 1157, 10.1001/archneur.64.8.1157 · DOI · Paper page
  122. Shiee, 2012, Revisiting brain atrophy and its relationship to disability in multiple sclerosis, PLoS One, 7, e37049, 10.1371/journal.pone.0037049 · DOI
  123. Calabrese, 2007, Cortical atrophy is relevant in multiple sclerosis at clinical onset, J Neurol, 254, 1212, 10.1007/s00415-006-0503-6 · DOI · Paper page
  124. Dale, 1999, Cortical surface-based analysis. I. segmentation and surface reconstruction, Neuroimage, 9, 179, 10.1006/nimg.1998.0395 · DOI · Paper page
  125. Nakamura, 2011, CLADA: cortical longitudinal atrophy detection algorithm, Neuroimage, 54, 278, 10.1016/j.neuroimage.2010.07.052 · DOI
  126. Nakamura, 2013, Jacobian integration method increases the statistical power to measure gray matter atrophy in multiple sclerosis, Neuroimage Clin, 4, 10, 10.1016/j.nicl.2013.10.015 · DOI
  127. Harrison, 2011, Longitudinal changes in diffusion tensor-based quantitative MRI in multiple sclerosis, Neurology, 76, 179, 10.1212/WNL.0b013e318206ca61 · DOI
  128. Fox, 2011, Measuring myelin repair and axonal loss with diffusion tensor imaging, AJNR Am J Neuroradiol, 32, 85, 10.3174/ajnr.A2238 · DOI
  129. Harrison, 2013, Tract-specific quantitative MRI better correlates with disability than conventional MRI in multiple sclerosis, J Neurol, 260, 397, 10.1007/s00415-012-6638-8 · DOI
  130. Schmierer, 2007, Quantitative magnetization transfer imaging in postmortem multiple sclerosis brain, J Magn Reson Imaging, 26, 41, 10.1002/jmri.20984 · DOI · Paper page
  131. Tortorella, 2000, A magnetization transfer histogram study of normal-appearing brain tissue in MS, Neurology, 54, 186, 10.1212/WNL.54.1.186 · DOI · Paper page
  132. Hayton, 2009, Grey matter magnetization transfer ratio independently correlates with neurological deficit in secondary progressive multiple sclerosis, J Neurol, 256, 427, 10.1007/s00415-009-0110-4 · DOI
  133. Hayton, 2012, Longitudinal changes in magnetisation transfer ratio in secondary progressive multiple sclerosis: data from a randomised placebo controlled trial of lamotrigine, J Neurol, 259, 505, 10.1007/s00415-011-6212-9 · DOI
  134. Geurts, 2005, Cortical lesions in multiple sclerosis: combined postmortem MR imaging and histopathology, AJNR Am J Neuroradiol, 26, 572
  135. Evangelou, 2005, Pathological study of spinal cord atrophy in multiple sclerosis suggests limited role of local lesions, Brain, 128, 29, 10.1093/brain/awh323 · DOI
  136. Oh, 2013, Multiparametric MRI correlates of sensorimotor function in the spinal cord in multiple sclerosis, Mult Scler, 19, 427, 10.1177/1352458512456614 · DOI
  137. Theaudin, 2012, Short-term evolution of spinal cord damage in multiple sclerosis: a diffusion tensor MRI study, Neuroradiology, 54, 1171, 10.1007/s00234-012-1057-1 · DOI
  138. Frohman, 2008, Optical coherence tomography: a window into the mechanisms of multiple sclerosis, Nat Clin Pract Neurol, 4, 664, 10.1038/ncpneuro0950 · DOI · Paper page
  139. Petzold, 2010, Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis, Lancet Neurol, 9, 921, 10.1016/S1474-4422(10)70168-X · DOI · Paper page
  140. Abalo-Lojo, 2014, Retinal nerve fiber layer thickness, brain atrophy, and disability in multiple sclerosis patients, J Neuroophthalmol, 34, 23, 10.1097/WNO.0000000000000057 · DOI
  141. Saidha, 2011, Visual dysfunction in multiple sclerosis correlates better with optical coherence tomography derived estimates of macular ganglion cell layer thickness than peripapillary retinal nerve fiber layer thickness, Mult Scler, 17, 1449, 10.1177/1352458511418630 · DOI · Paper page
  142. Narayanan, 2014, Tracking changes over time in retinal nerve fiber layer and ganglion cell-inner plexiform layer thickness in multiple sclerosis, Mult Scler, 20, 1331, 10.1177/1352458514523498 · DOI
  143. Ziemann, 2011, Development of biomarkers for multiple sclerosis as a neurodegenerative disorder, Prog Neurobiol, 95, 670, 10.1016/j.pneurobio.2011.04.007 · DOI
  144. Burman, 2014, Assessing tissue damage in multiple sclerosis: A biomarker approach, Acta Neurol Scand, 130, 81, 10.1111/ane.12239 · DOI
  145. Malmestrom, 2003, Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS, Neurology, 61, 1720, 10.1212/01.WNL.0000098880.19793.B6 · DOI · Paper page
  146. Gunnarsson, 2011, Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab, Ann Neurol, 69, 83, 10.1002/ana.22247 · DOI · Paper page
  147. Kuhle, 2013, Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis, Acta Neurol Scand, 128, e33, 10.1111/ane.12151 · DOI
  148. Semra, 2002, Heightened intrathecal release of axonal cytoskeletal proteins in multiple sclerosis is associated with progressive disease and clinical disability, J Neuroimmunol, 122, 132, 10.1016/S0165-5728(01)00455-6 · DOI
  149. Petzold, 2002, Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations, Brain, 125, 1462, 10.1093/brain/awf165 · DOI · Paper page
  150. Axelsson, 2011, Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis, J Neurol, 258, 882, 10.1007/s00415-010-5863-2 · DOI · Paper page
  151. Denic, 2011, The relevance of animal models in multiple sclerosis research, Pathophysiology, 18, 21, 10.1016/j.pathophys.2010.04.004 · DOI · Paper page
  152. Parmar, 2014, More multiarm randomised trials of superiority are needed, Lancet, 384, 283, 10.1016/S0140-6736(14)61122-3 · DOI · Paper page

Cited by

See all 220

Metadata

Authors
Ontaneda, D., Fox, R. J., & Chataway, J.
Venue
The Lancet Neurology
Publisher
Elsevier BV
Published
2015-02
Volume
14
Issue
2
Pages
208-223
ISSN
1474-4422 (ISSN-L)
OpenAlex
W2072808323
Cited by
220
References
17
FWCI
24.09
Type
journal article
Language
en
Open access
green
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives. https://app.cochat.ai/papers/10.1016/s1474-4422(14)70264-9
The paper
Ontaneda, D., Fox, R. J., & Chataway, J. (2015). Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(14)70264-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.